SCHOTT Pharma KGaA Past Earnings Performance
Past criteria checks 6/6
SCHOTT Pharma KGaA has been growing earnings at an average annual rate of 19.6%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 8% per year. SCHOTT Pharma KGaA's return on equity is 21.9%, and it has net margins of 17.5%.
Key information
19.6%
Earnings growth rate
19.6%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 8.0% |
| Return on equity | 21.9% |
| Net Margin | 17.5% |
| Next Earnings Update | 27 Jun 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How SCHOTT Pharma KGaA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 906 | 158 | 124 | 27 |
| 30 Sep 23 | 899 | 152 | 123 | 27 |
| 30 Jun 23 | 873 | 143 | 123 | 24 |
| 30 Sep 22 | 821 | 125 | 111 | 24 |
| 30 Sep 21 | 649 | 101 | 92 | 22 |
| 30 Sep 20 | 584 | 77 | 90 | 24 |
Quality Earnings: 1SXP has high quality earnings.
Growing Profit Margin: 1SXP's current net profit margins (17.5%) are higher than last year (15.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1SXP's earnings have grown by 19.6% per year over the past 5 years.
Accelerating Growth: 1SXP's earnings growth over the past year (20.5%) exceeds its 5-year average (19.6% per year).
Earnings vs Industry: 1SXP earnings growth over the past year (20.5%) exceeded the Life Sciences industry 6.5%.
Return on Equity
High ROE: 1SXP's Return on Equity (21.9%) is considered high.